Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 24, 2024, titled "Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)."